On November 1, the Federal Court of the Southern District of California, denied Certis motion to dismiss AntiCancer’s $28.1 million lawsuit against them.
SAN DIEGO--(BUSINESS WIRE)-- On November 1, the Federal Court of the Southern District of California, denied Certis motion to dismiss AntiCancer‘s $28.1 million lawsuit against them.
The lawsuit involves claims for trademark infringement, conversion (theft of property), quantum meruit (large unpaid fees) and fraud by Certis and it’s CEO, Peter Ellman.
The Court gave leave to AntiCancer to amend its trademark infringement claim; all other claims remain.
“I am very satisfied with our victory in federal court, " said AntiCancer founder Robert Hoffman. “Our case has much merit, and we look forward to proving all of our claims during the law suit,” said Dr. Hoffman. Attorney Matt Valenti is representing AntiCancer.
AntiCancer, founded in 1984, is the developer and marketer of the leading mouse models of patient cancer, PDOX. AntiCancer is the world’s leading preclinical cancer contract research organization, as well as developer of next generation cancer therapeutics.
AntiCancer’s world headquarters are in San Diego with subsidiaries in Japan, Korea and China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005165/en/
Source: AntiCancer
View this news release online at:
http://www.businesswire.com/news/home/20181105005165/en
